ES2558157T3 - Métodos para potenciar la capacidad adyuvante de las composiciones de vacunas - Google Patents
Métodos para potenciar la capacidad adyuvante de las composiciones de vacunas Download PDFInfo
- Publication number
- ES2558157T3 ES2558157T3 ES08875737.2T ES08875737T ES2558157T3 ES 2558157 T3 ES2558157 T3 ES 2558157T3 ES 08875737 T ES08875737 T ES 08875737T ES 2558157 T3 ES2558157 T3 ES 2558157T3
- Authority
- ES
- Spain
- Prior art keywords
- antigen
- adjuvant
- enhance
- methods
- vaccine compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title abstract description 14
- 239000000203 mixture Substances 0.000 title abstract description 11
- 239000002671 adjuvant Substances 0.000 title description 8
- 239000000427 antigen Substances 0.000 abstract description 11
- 102000036639 antigens Human genes 0.000 abstract description 11
- 108091007433 antigens Proteins 0.000 abstract description 11
- LIXVHWQNKBIZBR-ICAJWQFTSA-N 1-O-(6-acetamido-6-deoxy-alpha-D-galactosyl)-N-[(15Z)-tetracos-15-enoyl]phytosphingosine Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CNC(C)=O)[C@H](O)[C@H](O)[C@H]1O LIXVHWQNKBIZBR-ICAJWQFTSA-N 0.000 abstract description 10
- 230000028996 humoral immune response Effects 0.000 abstract description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract description 2
- 108010079723 Shiga Toxin Proteins 0.000 abstract 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 229940125898 compound 5 Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96873107P | 2007-08-29 | 2007-08-29 | |
| US968731P | 2007-08-29 | ||
| PCT/IB2008/003016 WO2010023498A1 (en) | 2007-08-29 | 2008-08-29 | Methods of enhancing adjuvanticity of vaccine compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2558157T3 true ES2558157T3 (es) | 2016-02-02 |
Family
ID=42061962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08875737.2T Active ES2558157T3 (es) | 2007-08-29 | 2008-08-29 | Métodos para potenciar la capacidad adyuvante de las composiciones de vacunas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8916164B2 (enExample) |
| EP (1) | EP2190475B1 (enExample) |
| JP (1) | JP5539890B2 (enExample) |
| KR (1) | KR101540081B1 (enExample) |
| CN (1) | CN101820909A (enExample) |
| AU (1) | AU2008360937B9 (enExample) |
| BR (1) | BRPI0815846A2 (enExample) |
| ES (1) | ES2558157T3 (enExample) |
| HR (1) | HRP20151356T1 (enExample) |
| PL (1) | PL2190475T3 (enExample) |
| PT (1) | PT2190475E (enExample) |
| RU (1) | RU2491090C2 (enExample) |
| WO (1) | WO2010023498A1 (enExample) |
| ZA (1) | ZA201001477B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0820960B8 (pt) | 2007-12-05 | 2021-05-25 | Abivax | composição, composição farmacêutica, e uso da composição |
| MY171201A (en) | 2012-04-26 | 2019-10-01 | Riken | New carbamate glycolipid and use thereof |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242800A (en) | 1990-01-30 | 1993-09-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Receptor for pathogenic fungi |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| TW261533B (enExample) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| ATE191916T1 (de) | 1992-10-22 | 2000-05-15 | Kirin Brewery | Neues sphingolglycolipid und verwendung davon |
| US5780441A (en) | 1993-04-15 | 1998-07-14 | Kirin Beer Kabushiki Kaisha | Sphingoglycolipid compounds and therapeutic uses thereof |
| CN1125449A (zh) | 1993-05-14 | 1996-06-26 | 萨依特尔有限公司 | 作为细胞粘附抑制剂的唾液基Lex类似物 |
| US6054433A (en) | 1994-11-03 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for stimulating tissue growth and epithelial moisturization |
| US5785975A (en) | 1995-06-26 | 1998-07-28 | Research Triangle Pharmaceuticals | Adjuvant compositions and vaccine formulations comprising same |
| EP0821068A3 (en) | 1996-03-29 | 1999-06-02 | Rohm And Haas Company | Novel sphingolipids and a process thereto |
| US6417167B1 (en) | 1997-02-05 | 2002-07-09 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing shingoglycolipid and process for preparing them |
| AU739673B2 (en) | 1997-02-05 | 2001-10-18 | Kirin Pharma Kabushiki Kaisha | Lyophilized compositions containing sphingoglycolipid and process for preparing them |
| EP1520583B1 (en) | 1997-04-10 | 2009-01-28 | Kyowa Hakko Kirin Co., Ltd. | NKT cell-activating agents containing alpha-glycosylceramides |
| CA2316041A1 (en) | 1997-12-30 | 1999-07-08 | Pam Fredman | Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications |
| EP1053243B1 (en) | 1998-02-12 | 2011-03-30 | Emory University | Sphingolipid derivatives and their methods of use |
| SE9900496D0 (sv) * | 1999-02-12 | 1999-02-12 | Pharmatrix Ab | Vaccine formulation |
| DE60041413D1 (de) * | 1999-10-12 | 2009-03-05 | Ca Nat Research Council | Archaeosome als adjuvantien und träger für azelluläre impstoffe zur induktion einer zytotoxischen t-lymphozyten (ctl) immunantwort |
| US20030157113A1 (en) | 1999-12-28 | 2003-08-21 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20030153514A1 (en) | 2000-04-28 | 2003-08-14 | Akikuni Yagita | Remedies for cancer |
| JP4410913B2 (ja) | 2000-06-12 | 2010-02-10 | 壽製薬株式会社 | 新規糖脂質誘導体の製造方法 |
| WO2001098317A2 (en) | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| AU2001286636A1 (en) | 2000-08-25 | 2002-03-13 | Lysometrix Corporation | Method for assaying the activity of lysosomal enzymes |
| AU2002327338A1 (en) | 2001-07-25 | 2003-02-17 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| KR100549866B1 (ko) | 2001-08-22 | 2006-02-08 | 고려대학교 산학협력단 | 암치료 및 예방 제제 |
| RU2360699C2 (ru) * | 2001-10-03 | 2009-07-10 | Новартис Вэксинес Энд Дайэгностикс Инк. | Композиции менингококковых вакцин с адъювантами |
| CN1578667A (zh) | 2001-11-06 | 2005-02-09 | 东方癌症治疗株式会社 | 抗癌组合物 |
| US7273853B2 (en) | 2002-05-13 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | 6-11 bicyclic ketolide derivatives |
| GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| WO2003105769A2 (en) | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| WO2004094444A1 (en) | 2003-03-20 | 2004-11-04 | Brigham Young University | 6'-amino-6'-deoxygalactosylceramides |
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| TWI329130B (en) * | 2003-06-19 | 2010-08-21 | Bestewil Holding Bv | Functionally reconstituted viral membranes containing adjuvant |
| GB0314682D0 (en) | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| CA2560969A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
| AU2005280163B2 (en) | 2004-08-27 | 2011-11-24 | Albert Einstein College Of Medicine, Inc. | Ceramide derivatives as modulators of immunity and autoimmunity |
| DK1786439T3 (da) | 2004-09-03 | 2010-07-12 | Univ Chicago | Fremgangsmåder til aktivering af NKT-celler |
| JP5090928B2 (ja) | 2004-12-28 | 2012-12-05 | ザ ロックフェラー ユニバーシティ | Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体 |
| DK1848813T3 (da) | 2005-01-28 | 2013-07-15 | Univ Brigham Young | Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler |
| KR100764678B1 (ko) | 2005-07-13 | 2007-10-09 | 재단법인서울대학교산학협력재단 | 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물 |
| BRPI0617687A2 (pt) | 2005-10-25 | 2011-08-02 | Ludwig Inst Cancer Res | composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica |
| WO2007118234A2 (en) | 2006-04-07 | 2007-10-18 | The Scripps Research Institute | Modified -galactosyl ceramides for staining and stimulating natural killer t cells |
| BRPI0621599B1 (pt) | 2006-04-27 | 2021-07-27 | Cellid Co., Ltd | Vacina baseada em células b carregadas com o ligante da célula t exterminadora natural e antígeno |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
| EP1938836A1 (en) | 2006-12-28 | 2008-07-02 | Universite Rene Descartes (Paris V) | Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells |
| KR100868959B1 (ko) | 2006-12-30 | 2008-11-17 | 재단법인서울대학교산학협력재단 | 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물 |
| EP2058011A1 (en) | 2007-11-07 | 2009-05-13 | Wittycell | Nkt cell activating gycolipids covalently bound antigens and/or drug |
| BRPI0820960B8 (pt) | 2007-12-05 | 2021-05-25 | Abivax | composição, composição farmacêutica, e uso da composição |
| US9220767B2 (en) | 2008-10-08 | 2015-12-29 | Abivax | Vaccine composition for use against influenza |
-
2008
- 2008-08-28 US US12/675,595 patent/US8916164B2/en not_active Expired - Fee Related
- 2008-08-29 WO PCT/IB2008/003016 patent/WO2010023498A1/en not_active Ceased
- 2008-08-29 AU AU2008360937A patent/AU2008360937B9/en not_active Ceased
- 2008-08-29 KR KR1020107006371A patent/KR101540081B1/ko not_active Expired - Fee Related
- 2008-08-29 CN CN200880111544A patent/CN101820909A/zh active Pending
- 2008-08-29 JP JP2010532672A patent/JP5539890B2/ja not_active Expired - Fee Related
- 2008-08-29 BR BRPI0815846A patent/BRPI0815846A2/pt not_active IP Right Cessation
- 2008-08-29 ES ES08875737.2T patent/ES2558157T3/es active Active
- 2008-08-29 PL PL08875737T patent/PL2190475T3/pl unknown
- 2008-08-29 RU RU2010111766/10A patent/RU2491090C2/ru not_active IP Right Cessation
- 2008-08-29 EP EP08875737.2A patent/EP2190475B1/en not_active Not-in-force
- 2008-08-29 PT PT88757372T patent/PT2190475E/pt unknown
- 2008-08-29 HR HRP20151356TT patent/HRP20151356T1/hr unknown
-
2010
- 2010-03-01 ZA ZA2010/01477A patent/ZA201001477B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20151356T1 (hr) | 2016-01-01 |
| AU2008360937A1 (en) | 2010-03-04 |
| PL2190475T3 (pl) | 2016-04-29 |
| CN101820909A (zh) | 2010-09-01 |
| EP2190475A1 (en) | 2010-06-02 |
| AU2008360937B2 (en) | 2014-01-16 |
| RU2491090C2 (ru) | 2013-08-27 |
| KR101540081B1 (ko) | 2015-07-29 |
| US8916164B2 (en) | 2014-12-23 |
| JP5539890B2 (ja) | 2014-07-02 |
| WO2010023498A8 (en) | 2010-04-15 |
| AU2008360937B9 (en) | 2014-02-13 |
| KR20100072211A (ko) | 2010-06-30 |
| EP2190475B1 (en) | 2015-10-28 |
| WO2010023498A1 (en) | 2010-03-04 |
| AU2008360937A2 (en) | 2010-04-29 |
| JP2011518760A (ja) | 2011-06-30 |
| ZA201001477B (en) | 2010-12-29 |
| RU2010111766A (ru) | 2011-10-10 |
| US20100285042A1 (en) | 2010-11-11 |
| PT2190475E (pt) | 2016-02-11 |
| BRPI0815846A2 (pt) | 2017-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7675048B2 (ja) | 油性アジュバント | |
| Pearse et al. | ISCOMATRIX® adjuvant for antigen delivery | |
| ES2539818T3 (es) | Vacunas contra la gripe multiepitópicas multiméricas | |
| US20180296663A1 (en) | Vaccine composition | |
| Dey et al. | Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens | |
| US20090304744A1 (en) | Methods of enhancing immune response in the intradermal compartment and compounds useful thereof | |
| ES2585810T3 (es) | Uso de un virus de la gripe y un adyuvante de emulsión de aceite en agua para inducir respuesta de células T CD4 y/o una respuesta de células B de memoria mejorada | |
| NO20082472L (no) | Vaksinesammensetninger omfattende en saponin adjuvant | |
| AR035586A1 (es) | Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn | |
| US20050255121A1 (en) | Molecules enhancing dermal delivery of influenza vaccines | |
| US20060121055A1 (en) | Compositions with enhanced immunogenicity | |
| US20230355749A1 (en) | Immunomodulatory Compounds And Use Thereof For The Treatment And/Or Prevention Of Infectious Diseases | |
| Poston et al. | Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum | |
| US20130344109A1 (en) | Immunogenic Compositions | |
| CN115996751A (zh) | 与离子液体佐剂有关的方法和组合物 | |
| KR20230129477A (ko) | 글리코알케올 및 면역자극제를 포함하는 아쥬반트 | |
| US20260108600A1 (en) | Methods and compositions relating to improved ionic liquid adjuvants | |
| JP5676452B2 (ja) | ワクチンアジュバント | |
| CN122070140A (zh) | 基于皂苷的佐剂及其表征方法 | |
| EP4241853A2 (en) | Compositions for induction of immune response | |
| US11400151B2 (en) | Methods for improving immunological response in vaccinated animals | |
| JP2022540197A5 (enExample) | ||
| CA3149593A1 (en) | Methods of increasing vaccine efficacy | |
| AU2021325648B2 (en) | Anti-coronavirus vaccines | |
| WO2025076039A1 (en) | Chlamydial protease-like activity factor and adjuvant compositions and uses thereof |